Patents by Inventor Eric M. Gordon

Eric M. Gordon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BETA-LACTAMASE INHIBITORS AND USES THEREOF
    Publication number: 20230201218
    Abstract: ?-Lactamase inhibiting compounds, therapeutic methods of using the ?-lactamase inhibiting compounds, particularly in combination with ?-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The ?-lactamase inhibiting compounds are suitable for oral administration.
    Type: Application
    Filed: February 28, 2023
    Publication date: June 29, 2023
    Applicant: Arixa Pharmaceuticals, Inc.
    Inventors: Eric M. Gordon, John Freund, Mark A. Gallop, Matthew Alexander James Duncton
  • Methods of synthesizing aztreonam derivatives
    Patent number: 11565999
    Abstract: Disclosed herein are aztreonam derivatives, therapeutic methods of using the aztreonam derivatives, and methods of synthesizing aztreonam derivatives. The aztreonam derivatives can be administered orally to provide orally bioavailable aztreonam.
    Type: Grant
    Filed: April 6, 2020
    Date of Patent: January 31, 2023
    Assignee: Arixa Pharmaceuticals, Inc.
    Inventors: Eric M. Gordon, Matthew A. J. Duncton, John Freund
  • Derivatives of relebactam and uses thereof
    Patent number: 11180500
    Abstract: Derivatives of relebactam, therapeutic methods of using the derivatives of relebactam, particularly in combination with ?-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The derivatives of relebactam are suitable for oral administration.
    Type: Grant
    Filed: October 1, 2019
    Date of Patent: November 23, 2021
    Assignee: Arixa Pharmaceuticals, Inc.
    Inventors: Eric M. Gordon, Matthew A. J. Duncton, John Freund
  • AZTREONAM DERIVATIVES AND USES THEREOF
    Publication number: 20210009580
    Abstract: Disclosed herein are aztreonam derivatives, therapeutic methods of using the aztreonam derivatives, particularly in combination with ?-lactamase inhibitors, and pharmaceutical compositions thereof. The aztreonam derivatives can be administered orally to provide orally bioavailable aztreonam.
    Type: Application
    Filed: September 18, 2020
    Publication date: January 14, 2021
    Inventors: ERIC M. GORDON, MATTHEW A.J. DUNCTON, JOHN FREUND
  • METHODS OF SYNTHESIZING AZTREONAM DERIVATIVES
    Publication number: 20200339507
    Abstract: Disclosed herein are aztreonam derivatives, therapeutic methods of using the aztreonam derivatives, and methods of synthesizing aztreonam derivatives. The aztreonam derivatives can be administered orally to provide orally bioavailable aztreonam.
    Type: Application
    Filed: April 6, 2020
    Publication date: October 29, 2020
    Applicant: ARIXA PHARMACEUTICALS, INC.
    Inventors: ERIC M. GORDON, MATTHEW A.J. DUNCTON, JOHN FREUND
  • Aztreonam derivatives and uses thereof
    Patent number: 10815228
    Abstract: Disclosed herein are aztreonam derivatives, therapeutic methods of using the aztreonam derivatives, particularly in combination with ?-lactamase inhibitors, and pharmaceutical compositions thereof. The aztreonam derivatives can be administered orally to provide orally bioavailable aztreonam.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: October 27, 2020
    Assignee: ARIXA PHARMACEUTICALS, INC.
    Inventors: Eric M. Gordon, Matthew A. J. Duncton, John Freund
  • BETA-LACTAMASE INHIBITORS AND USES THEREOF
    Publication number: 20200297733
    Abstract: ?-Lactamase inhibiting compounds, therapeutic methods of using the ?-lactamase inhibiting compounds, particularly in combination with ?-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The ?-lactamase inhibiting compounds are suitable for oral administration.
    Type: Application
    Filed: June 8, 2020
    Publication date: September 24, 2020
    Inventors: ERIC M. GORDON, JOHN FREUND, MARK A. GALLOP, MATTHEW ALEXANDER JAMES DUNCTON
  • Beta-lactamase inhibitors and uses thereof
    Patent number: 10722521
    Abstract: ?-Lactamase inhibiting compounds, therapeutic methods of using the ?-lactamase inhibiting compounds, particularly in combination with ?-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The ?-lactamase inhibiting compounds are suitable for oral administration.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: July 28, 2020
    Assignee: ARIXA PHARMACEUTICALS, INC.
    Inventors: Eric M. Gordon, John Freund, Mark A. Gallop, Matthew Alexander James Duncton
  • DERIVATIVES OF RELEBACTAM AND USES THEREOF
    Publication number: 20200102307
    Abstract: Derivatives of relebactam, therapeutic methods of using the derivatives of relebactam, particularly in combination with ?-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The derivatives of relebactam are suitable for oral administration.
    Type: Application
    Filed: October 1, 2019
    Publication date: April 2, 2020
    Applicant: ARIXA PHARMACEUTICALS, INC.
    Inventors: ERIC M. GORDON, MATTHEW A.J. DUNCTON, JOHN FREUND
  • BETA-LACTAMASE INHIBITORS AND USES THEREOF
    Publication number: 20200046724
    Abstract: ?-Lactamase inhibiting compounds, therapeutic methods of using the f-lactamase inhibiting compounds, particularly in combination with ?-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The ?-lactamase inhibiting compounds are suitable for oral administration.
    Type: Application
    Filed: October 16, 2019
    Publication date: February 13, 2020
    Applicant: ARIXA PHARMACEUTICALS, INC.
    Inventors: ERIC M. GORDON, JOHN FREUND, MARK A. GALLOP, MATTHEW ALEXANDER JAMES DUNCTON
  • Beta-lactamase inhibitors and uses thereof
    Patent number: 10500211
    Abstract: ?-Lactamase inhibiting compounds, therapeutic methods of using the ?-lactamase inhibiting compounds, particularly in combination with ?-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The ?-lactamase inhibiting compounds are suitable for oral administration.
    Type: Grant
    Filed: August 29, 2018
    Date of Patent: December 10, 2019
    Assignee: ARIXA PHARMACEUTICALS, INC.
    Inventors: Eric M. Gordon, John Freund, Mark A. Gallop, Matthew Alexander James Duncton
  • AZTREONAM DERIVATIVES AND USES THEREOF
    Publication number: 20190211006
    Abstract: Disclosed herein are aztreonam derivatives, therapeutic methods of using the aztreonam derivatives, particularly in combination with ?-lactamase inhibitors, and pharmaceutical compositions thereof. The aztreonam derivatives can be administered orally to provide orally bioavailable aztreonam.
    Type: Application
    Filed: March 12, 2019
    Publication date: July 11, 2019
    Inventors: ERIC M. GORDON, MATTHEW A.J. DUNCTON, JOHN FREUND
  • Aztreonam derivatives and uses thereof
    Patent number: 10280161
    Abstract: Disclosed herein are aztreonam derivatives, therapeutic methods of using the aztreonam derivatives, particularly in combination with ?-lactamase inhibitors, and pharmaceutical compositions thereof. The aztreonam derivatives can be administered orally to provide orally bioavailable aztreonam.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: May 7, 2019
    Assignee: ARIXA PHARMACEUTICALS, INC.
    Inventors: Eric M. Gordon, Matthew A. J. Duncton, John Freund
  • AZTREONAM DERIVATIVES AND USES THEREOF
    Publication number: 20190100516
    Abstract: Disclosed herein are aztreonam derivatives, therapeutic methods of using the aztreonam derivatives, particularly in combination with ?-lactamase inhibitors, and pharmaceutical compositions thereof. The aztreonam derivatives can be administered orally to provide orally bioavailable aztreonam.
    Type: Application
    Filed: October 1, 2018
    Publication date: April 4, 2019
    Inventors: ERIC M. GORDON, MATTHEW A.J. DUNCTON, JOHN FREUND
  • BETA-LACTAMASE INHIBITORS AND USES THEREOF
    Publication number: 20190022102
    Abstract: ?-Lactamase inhibiting compounds, therapeutic methods of using the ?-lactamase inhibiting compounds, particularly in combination with ?lactam antibiotics and pharmaceutical compositions thereof are disclosed. The ?-lactamase inhibiting compounds are suitable for oral administration.
    Type: Application
    Filed: August 29, 2018
    Publication date: January 24, 2019
    Inventors: ERIC M. GORDON, JOHN FREUND, MARK A. GALLOP, MATTHEW ALEXANDER JAMES DUNCTON
  • Deuterated O-sulfated beta lactam hydroxamic acids and deuterated N-sulfated beta lactams
    Patent number: 10093666
    Abstract: Provided herein are deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams, pharmaceutical compositions thereof and methods of treating infectious disease with deuterated compounds or pharmaceutical compositions thereof.
    Type: Grant
    Filed: January 24, 2018
    Date of Patent: October 9, 2018
    Assignee: ARIXA PHARMACEUTICALS, INC.
    Inventor: Eric M. Gordon
  • Beta-lactamase inhibitors and uses thereof
    Patent number: 10085999
    Abstract: ?-Lactamase inhibiting compounds, therapeutic methods of using the ?-lactamase inhibiting compounds, particularly in combination with ?-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The ?-lactamase inhibiting compounds are suitable for oral administration.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: October 2, 2018
    Assignee: ARIXA PHARMACEUTICALS, INC.
    Inventors: Eric M. Gordon, John Freund, Mark A. Gallop, Matthew Alexander James Duncton
  • Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
    Patent number: 10047077
    Abstract: Provided herein are deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams, pharmaceutical compositions thereof and methods of treating infectious disease with deuterated compounds or pharmaceutical compositions thereof.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: August 14, 2018
    Assignee: SKYLINE ANTIINFECTIVES, INC.
    Inventor: Eric M. Gordon
  • DEUTERATED O-SULFATED BETA LACTAM HYDROXAMIC ACIDS AND DEUTERATED N-SULFATED BETA LACTAMS
    Publication number: 20180148439
    Abstract: Provided herein are deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams, pharmaceutical compositions thereof and methods of treating infectious disease with deuterated compounds or pharmaceutical compositions thereof.
    Type: Application
    Filed: January 24, 2018
    Publication date: May 31, 2018
    Inventor: ERIC M. GORDON
  • DEUTERATED O-SULFATED BETA LACTAM HYDROXAMIC ACIDS AND DEUTERATED N- SULFATED BETA LACTAMS
    Publication number: 20170298057
    Abstract: Provided herein are deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams, pharmaceutical compositions thereof and methods of treating infectious disease with deuterated compounds or pharmaceutical compositions thereof.
    Type: Application
    Filed: April 13, 2017
    Publication date: October 19, 2017
    Inventor: Eric M. Gordon